Literature DB >> 27896509

Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators.

Hirohisa Okabe1,2, Daisuke Hashimoto1, Akira Chikamoto1, Morikatsu Yoshida3, Katsunobu Taki1, Kota Arima1, Katsunori Imai1, Yoshitaka Tamura3, Osamu Ikeda3, Takatoshi Ishiko1, Hideaki Uchiyama2, Toru Ikegami2, Norifumi Harimoto2, Shinji Itoh2, Yo-Ichi Yamashita4, Tomoharu Yoshizumi2, Toru Beppu4, Yasuyuki Yamashita3, Hideo Baba5, Yoshihiko Maehara2.   

Abstract

BACKGROUND: Prognostic indicators of the malignant potential of pancreatic neuroendocrine tumors (PNET) are limited. We assessed tumor shape and enhancement pattern on contrast-enhanced computed tomography as predictors of malignant potential.
METHODS: Sixty cases of PNET patients undergoing curative surgery from 2001 to 2014 were enrolled onto our retrospective study. Preoperative enhanced CTs were assessed, and criteria defined for regularly shaped and enhancing tumors (group 1), and irregularly shaped and/or enhancing tumors (group 2). The relation of tumor shape and enhancement pattern to outcome was assessed.
RESULTS: Interobserver agreement was substantial (kappa = 0.74). Group 2 (n = 24) was significantly correlated with synchronous liver metastasis (23 vs. 0 %), lymph node metastasis (36 vs. 3 %), pathologic capsular invasion (68 vs. 8 %), larger tumor size (30 vs. 12 mm), tumor, node, metastasis classification system (TNM) stage III/IV disease (46 vs. 3 %), and histologic grade 2/3 (41 vs. 0 %). Multivariate analysis revealed that tumor grade 2/3 and group 2 criteria correlated with tumor relapse (hazard ratio 6.5 and 13.6, P = 0.0071 and 0.039, respectively), and that only group 2 criteria were independently correlated with poor overall survival (hazard ratio 5.56e + 9, P = 0.0041).
CONCLUSIONS: Irregular tumor shape/enhancement on preoperative computed tomography is a negative prognostic factor after curative surgery for PNET.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27896509     DOI: 10.1245/s10434-016-5630-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

Review 1.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

2.  Preoperative prediction of lymph node metastasis in nonfunctioning pancreatic neuroendocrine tumors from clinical and MRI features: a multicenter study.

Authors:  Hai-Bin Zhu; Pei Nie; Liu Jiang; Juan Hu; Xiao-Yan Zhang; Xiao-Ting Li; Ming Lu; Ying-Shi Sun
Journal:  Insights Imaging       Date:  2022-10-08

3.  CT Enhancement and 3D Texture Analysis of Pancreatic Neuroendocrine Neoplasms.

Authors:  Mirko D'Onofrio; Valentina Ciaravino; Nicolò Cardobi; Riccardo De Robertis; Sara Cingarlini; Luca Landoni; Paola Capelli; Claudio Bassi; Aldo Scarpa
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379

Review 4.  Resectable pancreatic solid lesions: Time to move from surgical diagnosis?

Authors:  Alberto Larghi; Mihai Rimbaş; Gianenrico Rizzatti; Giuseppe Quero; Antonio Gasbarrini; Guido Costamagna; Sergio Alfieri
Journal:  Endosc Ultrasound       Date:  2020 Mar-Apr       Impact factor: 5.628

5.  Updated Trends in Imaging Practices for Pancreatic Neuroendocrine Tumors (PNETs): A Systematic Review and Meta-Analysis to Pave the Way for Standardization in the New Era of Big Data and Artificial Intelligence.

Authors:  Ephraïm Partouche; Randy Yeh; Thomas Eche; Laura Rozenblum; Nicolas Carrere; Rosine Guimbaud; Lawrence O Dierickx; Hervé Rousseau; Laurent Dercle; Fatima-Zohra Mokrane
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.